

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Applicants: Matti Sallberg *et al.* Conf. No.: 9697

Serial No.: 09/466,035 Group Art Unit: 1633

Filing Date: December 17, 1999 Examiner: A. Wehbe

For: COMPOSITIONS AND METHODS FOR TREATING INTRACELLULAR DISEASES



CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Patent and Trademark Office as first class mail in an envelope addressed: MAIL STOP Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on January 5, 2006.

Gyne Riser
By: Gyne Riser
Gyne Riser

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on PTO Form 1449, submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made.

This Supplemental Information Disclosure Statement is being filed:

- within three months of the filing date of the patent application.
- within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.

- before the mailing date of a first Office Action on the merits.
- after the mailing date of a first Office Action on the merits, but before the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, and accordingly is accompanied by:
 - the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);
or
 - the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or
 - No fee is owed by the applicant(s).
- In accordance with 37 C.F.R. § 1.129(a), this Information Disclosure Statement is being filed in connection with the first or second After Final Submission, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p), is attached.
- after the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), (see "Statement," and "Fees" below).
- Copies of the references listed on the attached PTO Form 1449, are enclosed herewith.

EXCEPT THAT:

- In view of the voluminous nature of reference @@, and the likelihood that this reference is available to the Examiner, copies are not enclosed herewith.
- In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.

If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Statement under 37 C.F.R. § 1.97(e)

The undersigned attorney hereby states that each item contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.

Fees

No Fee is owed by the applicant(s).

The Supplemental Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.

Method of Payment of Fees


Attached is a check in the amount of \$180.00. This form is submitted in duplicate.

Charge Deposit Account No. 03-1664 in the amount of \$180.00. This form is submitted in duplicate.

Please charge any deficiency or credit any overpayment to Deposit Account 03-1664.

No fee or Statement is required under 37 C.F.R. § 1.97(b).

Respectfully submitted,



Helen Lee
Registration No. 39,270

Dated: January 5, 2006

CHIRON CORPORATION
Intellectual Property Dept.
4560 Horton Street
Emeryville, CA 94608-2916
Telephone: (510) 923-2192
Facsimile: (510) 655-3542

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56, §1.97, AND §1.98

PTO-1449 FORM (MODIFIED)

SHEET 1 OF 1



ATTORNEY DOCKET NO.

PP001231.0105

SERIAL NO.

09/466,035

APPLICANTS:

Matti Sallberg et al.

EXAMINER:

A. Wehbe

FILING DATE:

December 17, 1999

CONFIRMATION NO.

9697

GROUP ART UNIT:

1633

U.S. PATENT DOCUMENTS

Examiner Initial	Ref. No.	Document No.	Date	Name	Class	Subclass	Filed

FOREIGN PATENT DOCUMENTS

Examiner Initial	Ref. No.	Document No.	Publication Date	Country	Class	Subclass	Translation YES NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Examiner Initial	Ref. No.	Description
	C2	Heath, A.W., "Cytokines as Immunological Adjuvants", in <i>Vaccine Design: The Subunit and Adjuvant Approach</i> , Eds. M.F. Powell et al. (NY: Plenum Press), Chapter 28 (1995).

EXAMINER'S SIGNATURE

DATE CONSIDERED

† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609.
Line through citation if not in conformance and not considered.
Include copy of this form in next communication to applicant.

* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).